July 22, 2026
FDA approves zidesamtinib for ROS1-positive non-small cell lung cancer
Patients with ROS1 lung cancer have a new option. On July 22, 2026, the FDA approved zidesamtinib, sold as Jideytro. The maker is Nuvalent, Inc.
U.S. Food & Drug Administration